Luminex, Myriad boasts top line growth, but Affymetrix sinks
This article was originally published in Clinica
Luminex, the developer of the xMAP multi-analyte profiling platform, has forecast a bullish revenue outlook for 2009, after it recorded robust top line growth for 2008, respectively. Describing 2008 as a "transformational year", the Austin, Texas firm said fourth-quarter revenue was up 31% to $28.3m. Growth during this period reflected an 18% rise in shipments of its analyser systems, as well as a 53% increase in consumable sales and 44% increase in royalty revenue. Gross profit margin also showed considerable improvement, widening 7 percentage points in the fourth quarter to 69%. However, reported net income plunged nearly 82% to $2m in 2008, due to the negative impact of one-off gains in the previous year that boosted earnings for Q4 2007. Excluding the gain on settlement of litigation and liability, Luminex had recorded a loss of $2.8m for Q4 2007, which meant it swung into profit for the same period in 2008. For the full year 2008, revenue was up 39% at $104.4m, gross profit margin increased from 61% to 68% and net income was $3.1m. Luminex anticipates maintaining double-digit growth rates for 2009. It expects full year revenue to grow between 25-34% to $130-140m.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.